Related references
Note: Only part of the references are listed.SOX4, SOX11 and PAX6 mRNA expression was identified as a (prognostic) marker for the aggressiveness of neuroendocrine tumors of the lung by using next-generation expression analysis (NanoString)
Robert Fred Henry Walter et al.
FUTURE ONCOLOGY (2015)
A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H
Keith C. Bible et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas
Michele Simbolo et al.
VIRCHOWS ARCHIV (2014)
Activation of Angiogenesis Differs Strongly Between Pulmonary Carcinoids and Neuroendocrine Carinomas and Is Crucial for Carcinoid Tumourgenesis
Fabian D. Mairinger et al.
JOURNAL OF CANCER (2014)
Differential Gene Expression of Medullary Thyroid Carcinoma Reveals Specific Markers Associated with Genetic Conditions
Agnieszka Maliszewska et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma
Cristina Rodriguez-Antona et al.
ENDOCRINE-RELATED CANCER (2013)
Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant and Mutually Exclusive Oncogenic Mutations in RET and RAS
Nishant Agrawal et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Platelet-derived growth factor receptor-α promotes lymphatic metastases in papillary thyroid cancer
Jingdong Zhang et al.
JOURNAL OF PATHOLOGY (2012)
RefGenes: identification of reliable and condition specific reference genes for RT-qPCR data normalization
Tomas Hruz et al.
BMC GENOMICS (2011)
Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
Laurie L. Carr et al.
CLINICAL CANCER RESEARCH (2010)
Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis
Cristina Rodriguez-Antona et al.
ENDOCRINE-RELATED CANCER (2010)
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
Elaine T. Lam et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
M. M. Moura et al.
BRITISH JOURNAL OF CANCER (2009)
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474
Francesca Carlomagno et al.
ENDOCRINE-RELATED CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer:: A 10-year follow-up study
Rossella Elisei et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells
Tom Donnem et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes
P. M. Pollock et al.
ONCOGENE (2007)
Prognosis of medullary thyroid carcinoma - Demographic, clinical, and pathologic predictors of survival in 1252 cases
Sanziana Roman et al.
CANCER (2006)
Tumor lymphangiogenesis and metastatic spread - New players begin to emerge
Marc G. Achen et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Mechanisms of disease:: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy
Matthias Drosten et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Somatic mutations of the protein kinase gene family in human lung cancer
H Davies et al.
CANCER RESEARCH (2005)
Fibroblast growth factor receptors as molecular targets in thyroid carcinoma
R St Bernard et al.
ENDOCRINOLOGY (2005)
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors
F Carlomagno et al.
ONCOGENE (2004)
Share Paper
